← Eichor
Study identifier: NCT04150198 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MECHANISMS OF NEURONAL RESILIENCE IN ALZHEIMER'S DISEASE AND ITS FOCAL VARIANTS: A PET/MR STUDY

Condition: Alzheimer Disease, Early Onset · Posterior Cortical Atrophy  ·  Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

PhaseNA
Planned participants45
Who can joinAll sexes, 40 Years to 80 Years
Healthy volunteersYes

About this study

Patients with Alzheimer's disease and with early onset of symptoms (\<65 years) (AD-Y) have a multi-domain cognitive deficit, whereas memory disorders (typical of the elderly patient's AD) are less often in the foreground. In addition, some MA-J have an atypical phenotype indicating focal brain damage, although they have the same pathological lesions: amyloid deposits and tau protein deposition (DNF). This is the case of posterior cortical atrophy (PCA) characterized by complex visual disturbances and atrophy affecting the more posterior regions of the brain. Based on the clinical profile of PCA patients, a more refined anatomo-clinical classification was proposed, distinguishing a rather "ventral" form and a rather "dorsal" form. The recent arrival of tau-specific PET tracers now makes it possible to evaluate in vivo fibrillary neurodegeneration (FND), which is well correlated with the severity of cognitive disorders. Advances in MRI have shown that each neurodegenerative syndrome targets a large-scale neural network, which in turn shows a vulnerability for a specific biological disease. In the case of AD, the reason for such a difference in cognitive and anatomical impairment between patients with diffuse involvement and others with more focal involvement is not known. One possible explanation is the existence, in focal forms, of neuronal mechanisms that oppose vulnerability. These mechanisms may correspond to the so-called "resilience" phenomenon, defined as resistance to …

This description comes directly from the study's public registry record.

Talk to the study team

Marie Odile Habert, MCU-PH  ·  01 57 27 40 00  ·  marie-odile.habert@aphp.fr

Raffaella Migliaccio, MD, PhD, HDR  ·  01 57 27 40 00  ·  raffaella.migliaccio@inserm.fr

Always discuss trial participation with your own doctor first.

Locations (2)

Service Hospitalier Frédéric Joliot SHFJOrsay, FranceRecruiting
Service de Médecine Nucléaire - Hopital La Pitié SalpetriereParis, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04150198